Long-term follow up of changes in FEV1 and treatment intensity during Pseudomonas aeruginosa colonisation in patients with cystic fibrosis.
about
Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosisIntravenous antibiotics for pulmonary exacerbations in people with cystic fibrosisIntravenous antibiotics for pulmonary exacerbations in people with cystic fibrosisAntibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosisInhaled anti-infective chemotherapy for respiratory tract infections: successes, challenges and the road aheadClinical applications of pulmonary delivery of antibioticsThe Pseudomonas aeruginosa AlgZR two-component system coordinates multiple phenotypes.Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial.Use of a modeling framework to evaluate the effect of a modifier gene (MBL2) on variation in cystic fibrosis.Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: the EVOLVE trial.Pseudomonas aeruginosa in children with cystic fibrosis diagnosed through newborn screening: assessment of clinic exposures and microbial genotypesClinical significance of microbial infection and adaptation in cystic fibrosis.Pseudomonas infection in antibody deficient patients.Proposal of a quantitative PCR-based protocol for an optimal Pseudomonas aeruginosa detection in patients with cystic fibrosis.Strong incidence of Pseudomonas aeruginosa on bacterial rrs and ITS genetic structures of cystic fibrosis sputaReducing bias in bacterial community analysis of lower respiratory infections.Clearance of initial mucoid Pseudomonas aeruginosa in patients with cystic fibrosis.Early eradication of Pseudomonas aeruginosa in patients with cystic fibrosis.Pseudomonas aeruginosa biofilm infections: from molecular biofilm biology to new treatment possibilities.Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis.Population pharmacokinetics of inhaled tobramycin powder in cystic fibrosis patients.Sodium nitrite-mediated killing of the major cystic fibrosis pathogens Pseudomonas aeruginosa, Staphylococcus aureus, and Burkholderia cepacia under anaerobic planktonic and biofilm conditions.Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision.Longitudinal development of initial, chronic and mucoid Pseudomonas aeruginosa infection in young children with cystic fibrosis.Cystic fibrosis transmembrane conductance regulator (CFTR)-mediated residual chloride secretion does not protect against early chronic Pseudomonas aeruginosa infection in F508del homozygous cystic fibrosis patients.
P2860
Q24188054-3AFA5F9B-BBA6-4E9D-B053-85DAB2FFCA7AQ24188313-ED3F8F1D-5CF3-436E-94A1-865476319B87Q24201445-5AF96317-3600-450F-B460-62C9D6CE0171Q24240388-71B8F365-B0D6-4660-8795-BB366F084E4EQ26822988-6E86B668-70E8-4311-BAAF-7478FFA72F98Q26996053-B76E7BAE-ABEB-4064-88F1-3C96C4D2E180Q33780971-668A2F06-5070-46ED-840E-2CEC136AA453Q33861117-180DFAFA-0751-40AD-941A-315596CE25BEQ33869527-F77C5C61-62BF-4008-81B4-C5940C41E88EQ33957168-852D0D25-D5D9-4F3D-8521-BF3542F79D4AQ34067203-7912A24E-8808-4655-B503-C373EF1BA5C5Q34491552-FDA797F4-4462-4CD0-963F-DE0C7E260A13Q34743061-B8A85D7B-DADD-4823-9C75-22EAE446D42FQ35006748-6AFC398B-D3D7-406A-9E40-DED8C886F526Q36304192-25F98E0D-EE76-4319-8547-F3E2C37ADF6BQ36702276-3795053C-477C-466A-910C-13D964BB14A5Q36999096-1559D16A-C8F2-446D-94C7-1BB55DA393FAQ37727308-C7EB5EA0-4B74-4162-BD51-12044A321A4CQ38268531-BC20169D-16EA-4D64-B3FB-0E7E6A94B668Q38821019-AAC52E43-5E07-4C00-8755-7B0D3EC9EF10Q41907045-E414FD1A-38C1-4024-ADC4-298D1F916B10Q42376062-145B7646-F572-43B8-A3C5-FB807DAEA795Q47664266-F7FCA3FF-FCFF-4415-B424-10F698ACF467Q47720458-C3CCD524-383B-4B8F-84CD-D84FFFF1AFBDQ51644964-1C79DADC-26AE-4940-9022-3E92E7537A7B
P2860
Long-term follow up of changes in FEV1 and treatment intensity during Pseudomonas aeruginosa colonisation in patients with cystic fibrosis.
description
1998 nî lūn-bûn
@nan
1998 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Long-term follow up of changes ...... patients with cystic fibrosis.
@ast
Long-term follow up of changes ...... patients with cystic fibrosis.
@en
type
label
Long-term follow up of changes ...... patients with cystic fibrosis.
@ast
Long-term follow up of changes ...... patients with cystic fibrosis.
@en
prefLabel
Long-term follow up of changes ...... patients with cystic fibrosis.
@ast
Long-term follow up of changes ...... patients with cystic fibrosis.
@en
P2093
P2860
P356
P1433
P1476
Long-term follow up of changes ...... patients with cystic fibrosis.
@en
P2093
Ballmann M
von der Hardt H
P2860
P304
P356
10.1136/THX.53.9.732
P407
P577
1998-09-01T00:00:00Z